Skip to main content

Table 1 Median (range) HGF parameters during phase 1, control vs. nadroparin group

From: Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications

HGF phase_1

control

nadroparin

p

Cmax (ng/ml)

1.58 (0.80-5.65)

6.41 (0.75-7.38)

0.087

Cmin (ng/ml)

0.60 (0.33-1.20)

1.76 (0.35-3.60)

0.037

Caverage (ng/ml)

0.74 (0.47-2.38)

2.99 (0.34-4.08)

0.065

Tmax (min)

367 (30–500)

93 (30–122)

0.043

AUCss (ng*min/ml)

534 (340–1714)

2157 (243–2938)

0.065

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us